Skip links

Eugene Zhukovsky Joins GO Therapeutics as Chief Technology Officer

Cambridge, Mass., Nov. 5, 2020 — GO Therapeutics, a company exploiting new advances in glycoproteomics to develop novel, multimodal first-in-class cancer therapeutics against intractable targets, today announced that Eugene Zhukovsky, Ph.D. has expanded his role in the Company, becoming Chief Technology Officer.

Dr. Zhukovsky is an accomplished leader in the development of immune-therapeutics, such as T-cell bispecifics and immune checkpoint inhibitors. In his new role, Dr. Zhukosky will be responsible for the design, production and clinical development of GO Therapeutics’ emerging portfolio of novel, cancer-specific immuno-therapies.

GO Therapeutics’ advanced glyco-targeting engine is uncovering thousands of novel and targetable cancer-specific cell surface epitopes. These targets will lead to next generation immuno-oncology therapies delivering a superior therapeutic index providing maximum benefit to patients.

Dr. Zhukovsky has more than two decades experience in biotherapeutics research and development. He applies optimized monospecific- and novel bispecific-antibody platforms to the development of immunotherapeutics for cancer, with a particular focus on leveraging the biology of immune checkpoint modulators. Most recently, Dr. Zhukovsky served as the chief scientific officer of Biomunex Pharmaceuticals, where he redirected the company’s strategic focus to immuno-oncology therapeutics by leveraging its bispecific antibody platform. Prior to that he served as the chief scientific officer of Affimed and held research positions at Boehringer Ingelheim, and Xencor. Dr. Zhukovsky received a Ph.D. in biochemistry from Brandeis University, and served his postdoctoral fellowship at Genentech.

“We are excited to have Eugene join GO’s leadership team,” said Constantine Theodoropulos, Chief Executive Officer, GO Therapeutics. “He is a well-known and highly respected expert in the field of bispecific antibodies and cell therapies, and his experience will be critical in the advancement of our novel therapies to the clinic.”

Dr. Zhukovsky added, “GO Therapeutics is exploiting a unique aspect of cancer cell biology to develop a new class of cancer therapies for previously intractable solid tumors. I look forward to helping advance GO’s portfolio of antibody-based cancer therapies that promise to throw open the therapeutic window for modalities that are today severely limited by toxicities.”

About GO Therapeutics

GO Therapeutics is applying the latest advances in glycobiology to create cancer drugs that are more potent and less toxic. GO Therapeutics’ cancer specific antibodies against tumor-specific antigens can be used in a multimodal approach to killing cancer, such as antibody-drug-conjugates, bispecific T-cell engagers and immune-based cell therapies. The company’s scientific team includes some of the leading scientific researchers and applied biologists in glycoproteomics. GO Therapeutics is based in Cambridge, MA.